PSTVHIGH SIGNALFINANCIAL10-K

PSTV underwent a dramatic capital restructuring that resulted in a 10x share dilution (from 17M to 172M shares) while simultaneously raising significant cash and eliminating negative stockholders' equity.

The massive 900%+ increase in share count indicates a heavily dilutive equity raise that provided the company with desperately needed capital, as evidenced by the cash position jumping from $76K to $4.3M. While this eliminated the balance sheet insolvency (stockholders' equity turned positive at $4.0M), existing shareholders experienced severe dilution, and the company's cash burn actually accelerated with operating cash flow worsening from -$10.6M to -$20.8M.

Comparing 2026-03-12 vs 2025-03-31View on EDGAR →
FINANCIAL ANALYSIS

The financial picture shows a company that executed an emergency capital raise to avoid potential bankruptcy, with cash increasing 5,500% and total assets growing 146%, while shares outstanding increased by nearly 10x indicating massive dilution. Despite improved gross profit margins turning positive at $146K, the company's cash burn accelerated significantly with operating cash flow deteriorating to -$20.8M and net losses deepening to -$22.4M. The dramatic inventory reduction from $2.9M to $107K suggests either asset sales or write-downs, while the overall picture signals a company that narrowly avoided insolvency through heavily dilutive financing but continues to burn cash at an unsustainable rate.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+5500%
$76K$4.3M

Cash position surged 5500% — strong cash generation or capital raise providing significant financial cushion.

Gross Profit
P&L
+830%
-$20K$146K

Gross profit expanding — improving pricing power or product mix shift toward higher-margin offerings.

Current Assets
Balance Sheet
+188.5%
$5.3M$15.2M

Current assets grew 188.5% — improving short-term liquidity or inventory/receivables build.

Total Assets
Balance Sheet
+146.1%
$6.6M$16.3M

Asset base grew 146.1% — expansion through organic growth, acquisitions, or capital deployment.

Stockholders Equity
Balance Sheet
+144.7%
-$8.9M$4.0M

Equity base grew 144.7% — retained earnings accumulation or equity issuance strengthening the balance sheet.

Operating Cash Flow
Cash Flow
-96.8%
-$10.6M-$20.8M

Operating cash flow fell 96.8% — earnings quality concerns; investigate working capital changes and non-cash items.

Inventory
Balance Sheet
-96.4%
$2.9M$107K

Inventory drawn down 96.4% — strong sell-through or deliberate destocking; watch for supply constraints.

Net Income
P&L
-72.5%
-$13.0M-$22.4M

Net income declined 72.5% — review whether driven by operations, interest costs, or non-recurring items.

Capital Expenditure
Cash Flow
-54.1%
$146K$67K

Capex reduced 54.1% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Interest Expense
P&L
-44.4%
$711K$395K

Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.

LANGUAGE CHANGES
NEW — 2026-03-12
PRIOR — 2025-03-31
ADDED
As of March 10, 2026, there were 171,550,698 shares of the registrant s common stock issued and outstanding.
These statements include, without limitation, statements about our anticipated expenditures, including research and development, and general and administrative expenses; our intent or ability to regain and maintain compliance with Nasdaq listing standards; our strategic collaborations and license agreements, intellectual property, U.S.
healthcare company developing and commercializing precision diagnostics and targeted radiopharmaceuticals for central nervous system ( CNS ) cancers.
CNSide Diagnostics, LLC ( CNSide Diagnostics ) is our wholly owned subsidiary that develops and commercializes proprietary laboratory-developed tests, such as CNSide , designed to identify tumor cells that have metastasized to the central nervous system in patients with carcinomas and melanomas.
In radiopharmaceuticals, our lead candidate, rhenium ( 186 Re) obisbemeda, is designed specifically for CNS cancers including recurrent glioblastoma ( GBM ), leptomeningeal metastases ( LM ), and pediatric brain cancers ( PBC ) by direct localized delivery utilizing approved standard-of-care tissue access such as with convection-enhanced delivery ( CED ) and intraventricular brain (Ommaya reservoir) catheters.
+7 more — sign up free →
REMOVED
As of March 21, 2025, there were 16,999,626 shares of the registrant s common stock issued and outstanding.
Security Ownership of Certain Beneficial Owners and Management and Related Stockholder Matters 103 Item 13.
Form 10-K Summary 104 CAUTIONARY STATEMENT REGARDING FORWARD-LOOKING STATEMENTS This report contains certain statements that may be deemed forward-looking statements within the meaning of U.S.
These statements include, without limitation, statements about our anticipated expenditures, including research and development, and general and administrative expenses; our strategic collaborations and license agreements, intellectual property, U.S.
4 Risk Factor Summary Below is a summary of the principal factors that may affect our business, financial condition, and results of operations.
+7 more — sign up free →
MORE FINANCIAL SIGNALS
PNRGHIGHPNRG achieved exceptional profitability improvement with net income surging 2,21...
2026-04-16
BNAIHIGHBNAI underwent a dramatic reverse stock split that reduced share count by 86% wh...
2026-04-16
LAKEHIGHLAKE's financial performance deteriorated significantly with operating losses wo...
2026-04-16
NXXTHIGHNextNRG experienced massive financial deterioration with operating losses explod...
2026-04-16
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →